MBRX
What one share of Moleculin Biotech holds
Pharmaceutical Preparations
We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which we believe is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML).
Moleculin Biotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$9.60 |
| Cash and investments | $1.02 |
| Book value | $1.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.00 | −$1,032 | $36.22 | −$1,096 | — | $1,126 |
| 2019 | $0.00 | −$729.62 | $2.87 | −$953.12 | — | $766.15 |
| 2020 | $0.00 | −$661.01 | $14.32 | −$691.18 | — | $577.29 |
| 2021 | $0.00 | −$221.77 | $0.27 | −$264.69 | — | $1,037 |
| 2022 | $0.00 | −$380.51 | $0.88 | −$363.22 | — | $683.66 |
| 2023 | $0.00 | −$376.71 | $1.57 | −$300.10 | — | $347.11 |
| 2024 | $0.00 | −$189.14 | $0.09 | −$173.36 | — | $82.93 |
| 2025 | $0.00 | −$28.42 | $0.00 | −$19.19 | — | $4.69 |